Revision of Precautions
Cyclophosphamide hydrate

March 24, 2015

Non-proprietary name
Cyclophosphamide hydrate

Safety measure
Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following texts should be added (underlined parts are revised):

**Rhabdomyolysis:**
Rhabdomyolysis characterized by myalgia, feelings of weakness, increased creatine kinase (creatine phosphokinase), increased blood myoglobin, and increased urine myoglobin may occur.
Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.